Ginkgo Bioworks Holdings Current Ratio 2020-2022 | DNA

Ginkgo Bioworks Holdings current ratio from 2020 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Ginkgo Bioworks Holdings Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-03-31 $1.71B $0.16B 10.71
2021-12-31 $1.72B $0.14B 12.79
2021-09-30 $1.81B $0.09B 20.05
2021-06-30 $0.00B $0.01B 0.21
2021-03-31 $0.00B $0.00B 2.10
2020-12-31 $0.00B 0.00
2020-09-30 $0.00B 0.00
2019-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $4.957B $0.314B
Ginkgo Bioworks platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks, formerly known as Soaring Eagle Acquisition Corp., is based in NEW YORK.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $170.283B 10.36
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.670B 16.84
Biohaven Pharmaceutical Holding (BHVN) United States $10.157B 0.00
Arcus Biosciences (RCUS) United States $1.815B 46.02
Emergent Biosolutions (EBS) United States $1.640B 7.02
Myovant Sciences (MYOV) United Kingdom $1.243B 0.00
Zymeworks (ZYME) Canada $0.354B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.098B 0.00
Ambrx Biopharma (AMAM) United States $0.098B 0.00
SQZ Biotechnologies (SQZ) United States $0.095B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00